Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8937931 | 0.83 | — | — | |
| SCHEMBL8606746 | 0.79 | HRH4 (0.47) | DRD2DRD4DRD3 | |
| SCHEMBL11384661 | 0.78 | HTR3A (0.50) | DRD2DRD4DRD3 | |
| Methyl Alcohol SCHEMBL9719610 | 0.78 | MAOA (0.36) | DRD2DRD4DRD3MAOA | |
| SCHEMBL5765872 | 0.78 | GBA1 (0.41) | DRD2DRD4DRD3MAOAALOX5 | |
| SCHEMBL6146843 | 0.76 | GBA1 (0.53) | — | |
| SCHEMBL3832422 | 0.73 | DAO (0.38) | — | |
| SCHEMBL351813 | 0.71 | — | — | |
| SCHEMBL10640654 | 0.69 | MEN1 (0.35) | DRD2DRD4DRD3MAOAALOX5 | |
| SCHEMBL13790886 | 0.68 | MAOA (0.34) | DRD2DRD4DRD3MAOAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598394-B2 | Process for the synthesis of imidazoles | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070185332-A1 | PROCESS FOR THE SYNTHESIS OF IMIDAZOLES | ALLERGAN, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185332-A1 | PROCESS FOR THE SYNTHESIS OF IMIDAZOLES | LSS, SI, NISCH | DRD2 1990/4885DRD4 919/4885DRD3 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.